ROME—Although combination immunochemotherapy —rather than single agent chlorambucil — is widely used among younger patients with chronic lymphocytic leukaemia as a means of improving outcome, the reco
Peter Hillmen
ROME—Although combination immunochemotherapy —rather than single agent chlorambucil — is widely used among younger patients with chronic lymphocytic leukaemia as a means of improving outcome, the recommendation to use such combination therapy in older patients has not been so clear, according to Peter Hillmen, Professor of Haematology at the University of Leeds, who discussed this dursing the Rome conference on Blood Cancer in The Elderly. He talks with ecancer radio about the clinical implications of recent study findings.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110416PeterHillmanPODCASTLoRes.mp3]